A Phase III Randomized Study of BBI608 and Best Supportive Care Versus Placebo and Best Supportive Care in Patients With Pretreated Advanced Colorectal Carcinoma
Latest Information Update: 18 Oct 2023
Price :
$35 *
At a glance
- Drugs Napabucasin (Primary)
- Indications Colorectal cancer
- Focus Registrational; Therapeutic Use
- Sponsors Boston Biomedical; Sumitomo Pharma Oncology
- 11 Oct 2016 Results assessing efficacy and analysing biomarker for response, presented at the 41st European Society for Medical Oncology Congress
- 06 Oct 2016 According to a Sumitomo Dainippon Pharma media release, study results will be presented at the ESMO 2016 Congress
- 06 Oct 2016 Results published in the Sumitomo Dainippon Pharma media release.